.png){kind=icon}
.png){kind=icon}
Return
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting
.png){kind=icon}
OA
AI
DOI：10.1016/j.molcel.2020.07.027.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.
Keywords:
RESPIRATORY SYNDROME-CORONAVIRUS
SARS-CORONAVIRUS
MORPHOLINO-OLIGOMERS
STRUCTURAL BASIS
REPLICATION FIDELITY
LETHAL MUTAGENESIS
NUCLEOTIDE ANALOGS
FAVIPIRAVIR T-705
INFLUENZA-VIRUS
IN-VITRO
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
16.6
Papers:
1.0W
Citations:
8.5W
View more organizations